clinical trial · NCT07758634
A Trial Evaluating Safety, Tolerability and Efficacy of CTX340 in Participants With Hypertension
HypertensionCTX340Placebo
brief summary
A Study of CTX340 in Participants with Uncontrolled Hypertension.
started
Sep 25, 2026
primary completion
Jul 1, 2028
completion
Jul 1, 2029
last updated
Nov 12, 2026
detailed description
This is a dose ascending study of CTX340 in participants with hypertension. Subjects will receive CTX340 or placebo via intravenous (IV) infusion.
official title
A Phase 1/2 Multicenter, First-in-human, Ascending Dose Trial Evaluating the Safety, Tolerability, and Efficacy of a Lipid Nanoparticle Formulation of CRISPR-Guide RNA-Cas9 Nuclease (CTX340) for In Vivo Editing of the Angiotensinogen (AGT) Gene in Participants With Hypertension
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol